PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan

Int J Clin Oncol. 2024 May;29(5):493-494. doi: 10.1007/s10147-024-02510-6.

Authors

Noriomi Matsumura^{1

2}, Masaki Mandai^{3

4}

Affiliations

¹ Faculty of Medicine, Kindai University, Osaka-Sayama, Japan. noriomi@med.kindai.ac.jp.
² Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan. noriomi@med.kindai.ac.jp.
³ Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan.
⁴ Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 38551728
DOI: 10.1007/s10147-024-02510-6

No abstract available

Publication types

Editorial

MeSH terms

Activin Receptors, Type II*
Breast Neoplasms* / drug therapy
Drug Approval*
Female
Humans
Immunoglobulin Fc Fragments*
Japan
Male
Myelodysplastic Syndromes* / drug therapy
Phthalazines* / therapeutic use
Prostatic Neoplasms* / drug therapy
Recombinant Fusion Proteins / therapeutic use

Substances

Phthalazines
luspatercept
Recombinant Fusion Proteins
Immunoglobulin Fc Fragments
Activin Receptors, Type II